UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35986 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or ...

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2022 Earnings Conference Call February 21, 2023 8:00 AM ET Company Participants Tiffany Aldrich - Associate Director, Corporate Communications Sheldon Koenig - President and Chief Executive Officer JoAnne Foody - Chief Medical Officer Benjamin Halladay - CFO Eric Warren - Chief Commercial Officer Conference Call Participants Serge Belanger - Needham Joseph Thome - Cowen Michael Yee - Jefferies Jason Butler - JMP Securities Jeff Hung - Morgan Stanley Tom Shrader - ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35986 Esperion Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 26-1870780 (State or Other Jurisdi ...

Call Start: 08:00 January 1, 0000 8:39 AM ET Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q3 2022 Earnings Conference Call November 1, 2022 08:00 ET Company Participants Tiffany Aldrich - Associate Director, Corporate Communications Sheldon Koenig - President & Chief Executive Officer JoAnne Foody - Chief Medical Officer Eric Warren - Chief Commercial Officer Benjamin Halladay - Senior Director of Finance Conference Call Participants Mike Yee - Jefferies Serge Belanger - Needham & Company Tom Shrader - BTIG Mi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35986 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 26-1870780 (State or other jurisdict ...

WHEN DO YOU PLAN TO GET YOUR NEXT CHOLESTEROL TEST? ESPERION CORPORATE PRESENTATION August 2022 FORWARD-LOOKNG STATEMENTS & DISCLOSURES This presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization plans, restructuring and current and planned operational expenses, future operations, commercial products, clinical development including the timing, designs and pla ...

WHEN DO YOU PLAN TO GET YOUR NEXT CHOLESTEROL TEST? ESPERION Q2 2022 EARNINGS PRESENTATION AUGUST 2, 2022 © 2022 Esperion. All Rights Reserved – For investor audience only FORWARD-LOOKNG STATEMENTS & DISCLOSURES This presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization plans, current and planned operational expenses, future operations, commercial products, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35986 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 26-1870780 (State or other jurisdiction o ...

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q1 2022 Earnings Conference Call May 3, 2022 8:00 AM ET Company Participants Tiffany Aldrich - Senior Manager, Corporate Communications Sheldon Koenig - President and Chief Executive Officer Joanne Foody - Chief Medical Officer Eric Warren - Chief Commercial Officer BJ Swartz - Chief Strategy Officer Conference Call Participants Serge Belanger - Needham Jason Butler - JMP Securities Jessica Fye - JPMorgan Jeff Hung - Morgan Stanley Joseph Thome - Cowen Paul Choi - G ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | --- | |----------------------------------------------------------------|------------------------------------------------------------------------------------------------------------ ...